PHARMA FUSION
LIVE

Serial Number

99444231

Owner

Pharma Fusion LLC

Attorney

Lindsay Calhoun

First Use Date

Jul 1, 2024

Filing Date

Oct 15, 2025

Add to watchlist:

No watchlists yet
View on USPTO

PHARMA FUSION Trademark

Serial Number: 99444231

PHARMA FUSION is a trademark filed by Pharma Fusion LLC on October 15, 2025. The trademark is classified under Class 5 (Pharmaceuticals), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

Pharma Fusion LLC

518 Pujo Street
Lake Charles, LA 70601

Entity Type: 16

Trademark Details

Filing Date

October 15, 2025

Registration Date

Not Registered

First Use Anywhere

July 1, 2024

First Use in Commerce

July 1, 2024

Goods & Services

Business consulting services in the field of healthcare, featuring AI-driven automation tools designed to optimize patient recovery outcomes, reduce hospital and clinical visits, and support accurate medication recommendations; providing data analytics and predictive modeling services for healthcare providers to enhance treatment efficiency and patient engagement; business management and advisory services for medical practices integrating artificial intelligence technologies to streamline care delivery and improve operational performance.

Prescribed medications through the use of AI-driven automation tools designed to optimize patient recovery outcomes, reduce hospital and clinical visits, and support accurate medication recommendations, namely, providing prescribed medications to individuals using home infusion therapy, that is, the intravenous or subcutaneous administration of drugs or biologicals to an individual at home or at other sites outside of medical facilities.

Pharmacy services, namely, home infusion specialty pharmacy services to provide medically necessary infusion therapies to patients in their homes or other sites outside of medical facilities, and pharmacy services to health care providers to assist in prescribing medically appropriate and cost-effective treatment to patients; Prescribed medications through the use of AI-driven automation tools designed to optimize patient recovery outcomes, reduce hospital and clinical visits, and support accurate medication recommendations, namely, providing prescribed medications to individuals using home infusion therapy, that is, the intravenous or subcutaneous administration of drugs or biologicals being home health care services to an individual at home or at other sites outside of medical facilities.

Filing History

NOTIFICATION OF FINAL REFUSAL EMAILED
May 19, 2026 GNFN
FINAL REFUSAL E-MAILED
May 19, 2026 GNFR
FINAL REFUSAL WRITTEN
May 19, 2026 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 24, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 24, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 24, 2026 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 12, 2026 GNRN
NON-FINAL ACTION E-MAILED
Mar 12, 2026 GNRT
NON-FINAL ACTION WRITTEN
Mar 12, 2026 CNRT
ASSIGNED TO EXAMINER
Mar 3, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 11, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Oct 15, 2025 MAFR
NEW APPLICATION ENTERED
Oct 15, 2025 NWAP